Drug firm Cadila Healthcare on Wednesday reported a 26.78 decline in consolidated net profit at Rs 373.9 crore for the quarter ended December, mainly on account of rise in expenses.
The company had posted a net profit of Rs 510.7 crore for the corresponding period of the previous fiscal, Cadila Healthcare said in a filing to the BSE.
Total revenue from operations stood at Rs 3,638.1 crore for the quarter under review as compared with Rs 3,577.9 crore in the year-ago period.
"During the quarter, the company launched 9 new products in the US which included a day one launch. The company filed 14 additional abbreviated new drug applications (ANDAs) with the United States Food and Drug Administration (USFDA) taking the cumulative number of filings to 386," Cadila Healthcare said.
The company received eight new product approvals (including two tentative approvals) from the USFDA during the quarter, it added.
It launched oral anti-diabetic agent, Vinglyn and Vinglyn M in India during the quarter, Cadila Healthcare said.
Shares of Cadila Healthcare on Wednesday closed 2.71 per cent higher at Rs 271.20 per scrip on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app